DATATRAK International Reports First Quarter Result...(intellectualproperty rights; the Company...),Health

Date:5/8/2008

intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

DATATRAK International, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet Data

(Unaudited)

March 31, December 31,

2008 2007

Cash and investments $5,950,860 $8,514,361

Accounts receivable, net 1,395,989 1,070,688

Property & equipment, net 3,214,069 3,534,799

Deferred tax assets 1,301,700 1,399,000

Intangible assets, net 333,808 520,458

Goodwill 10,856,113 10,856,113

Other 511,102 577,792

Total assets $23,563,641 $26,473,211

Accounts payable and other current

liabilities $6,452,693 $3,971,883

Long-term liabilities 2,674,241 5,931,962

Shareholders' equity
'/>"/>

SOURCE DATATRAK International, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
2. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
6. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
7. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
8. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
9. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
10. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis